A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients
Status:
Not yet recruiting
Trial end date:
2026-09-30
Target enrollment:
Participant gender:
Summary
This is a randomized, open-label, multicenter Phase 3 clinical study to evaluate SKB264
monotherapy versus pemetrexed in combination with platinum in subjects with locally advanced
or metastatic non-squamous NSCLC with EGFR mutation who have failed to EGFR-TKI therapy.
Phase:
Phase 3
Details
Lead Sponsor:
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.